thebench.bio

Clinical Daily Summary

Clinical Daily Summary: What Happened on October 8, 2026

Argenx ends Phase 3 Sjögren’s trial after futility review

The day also brought new data on inherited cancer testing, a first-in-human trial clearance and Taiwan approvals for a lung-cancer study.

  • Updated
  • Read from 5 articles, 3 publications

Today in brief

Argenx ended its Phase 3 UNITY study of efgartigimod in Sjögren’s disease after a review concluded it was unlikely to meet its primary endpoint.12 The company reported no new safety signals. Its shares fell about 18% in Brussels trading.12

Argenx halts its Sjögren’s trial after interim analysis

An independent monitoring committee recommended ending UNITY for futility, meaning the trial was unlikely to show the required benefit.12 Argenx had expected results in the second half of 2027.1

Argenx plans to review the full dataset after the trial closes and the database is locked.12 Sjögren’s is an autoimmune disease with no approved disease-modifying treatments, though some biologics are used off-label.2

Argenx said its Phase 2 study of FB102 met its primary endpoint in celiac disease and that it plans to advance the drug into Phase 3.1 The company plans to present the data at a future medical meeting and continue testing FB102 in vitiligo and alopecia areata.1

Also worth knowing

  • Memorial Sloan Kettering researchers analyzed nearly 40,000 adults across 32 solid tumor types and estimated that age cutoffs could exclude 72% of people carrying pathogenic inherited variants. Finding these variants can inform treatment, cancer surveillance and testing of relatives.3

  • The FDA cleared Dignify Therapeutics’ investigational new drug application for DTI-117, an on-demand treatment candidate for neurogenic bowel dysfunction. The company plans to dose its first healthy volunteer in November.4

  • Lantern Pharma received regulatory and ethics clearances in Taiwan to start the next part of its Phase 2 HARMONIC study, testing LP-300 with chemotherapy in lung cancer. The revised protocol allows up to eight treatment cycles, up from six.5

Also published